BDD’s OralogiK™ Technology Powers Advancement of A Once-Daily Anxiety Treatment
BDD Pharma Ltd. is pleased to announce the advancement of another OralogiK™ powered product towards the clinic.
BDD’s OralogiK™ technology is integral to Cingulate Inc.’s once-daily buspirone formulation, CTx-2103, aimed at treating anxiety disorders. This milestone follows Cingulate’s recent announcement of securing a $3 million non-dilutive grant from a private foundation to accelerate the clinical development of CTx-2103.
OralogiK™ is BDD’s patented erosion-based, tablet-in-tablet technology designed to deliver precise, controlled drug release profiles. By incorporating an erodible barrier layer around the drug-containing core, OralogiK™ enables timed, pulsatile, or sustained release of active pharmaceutical ingredients (APIs), independent of gastrointestinal pH, hydrodynamics, or microbiome factors. This flexibility allows for tailored drug delivery profiles, including dual or triple-pulse dosing, targeted release to specific regions of the gastrointestinal tract, and fixed-dose combinations.
CTx-2103 utilises OralogiK™ to create a once-daily, multi-release formulation of buspirone, improving patient compliance and therapeutic outcomes for those suffering from anxiety disorders. The continued collaboration between BDD and Cingulate exemplifies the application of advanced drug delivery technologies to develop improved patient therapies.
Dr. Carol Thomson, CEO of BDD Pharma, commented: “We are proud to see our OralogiK™ technology contributing to the development of further innovative treatments like CTx-2103. This partnership underscores our commitment to enhancing drug delivery solutions that improve patient lives.”
This development builds upon the existing collaboration between BDD and Cingulate, which includes the advancement of CTx-1301, a triple-pulse dexmethylphenidate product for ADHD, also employing BDD’s OralogiK™ technology.
“We appreciate our continued partnership with BDD Pharma and look forward to advancing the development of CTx-2103,” said Cingulate Chairman and CEO Shane J. Schaffer. “This funding enhances Cingulate’s pipeline and brings us one step closer to providing the first, once-daily medicine for the millions of patients worldwide who suffer from anxiety-related disorders, the most common mental health issue in America and around the world.”
About BDD Pharma Ltd.
BDD Pharma Ltd. is a UK-based contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) specialising in oral drug formulation, GMP manufacturing, and early-phase clinical trials. With over 25 years of experience, BDD offers integrated services to streamline the path to Phase I clinical data, leveraging proprietary technologies like OralogiK™ to optimise drug delivery and therapeutic outcomes.
About OralogiK™
OralogiK™ is BDD’s proprietary controlled-release technology that enables precise timing of drug release within the gastrointestinal tract. By employing a bespoke erodible barrier layer around the drug core, OralogiK™ allows for customisable release profiles, including delayed, sustained, and pulsatile delivery, enhancing the efficacy and patient adherence of oral medications.
About Cingulate Inc.
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.
About CTx-2103
CTx-2103 is a novel, multi-release tablet of buspirone that incorporates Cingulate’s proprietary PTR™ drug delivery platform. CTx-2103 is being studied for the treatment of anxiety and/or anxiety-related disorders. Buspirone, an azapirone derivative and a 5-HT1A partial agonist, was the first non-benzodiazepine anxiolytic introduced for the treatment of generalized anxiety disorder. Buspirone may exhibit a decreased side-effect profile compared to other anxiolytic treatments. Unlike benzodiazepines and barbiturates, there is no associated risk of physical dependence or withdrawal with buspirone use due to the lack of effects on gamma-aminobutyric acid receptors.
For more information, please visit: www.bddpharma.com
ENDS